OCGN vs PALI

Ocugen, Inc. vs Palisade Bio, Inc. — Valuation Comparison 2026

OCGN

Biological Products, (No Diagnostic Substances)
Ocugen, Inc.
Quality
6.6
out of 10
Value Trap
26
LOW
Price
$1.38
Last close
Models
8/13
Active
VS

PALI

Biological Products, (No Diagnostic Substances)
Palisade Bio, Inc.
Quality
4.0
out of 10
Value Trap
27
LOW
Price
$2.12
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType OCGN Fair ValueOCGN Upside PALI Fair ValuePALI Upside
Bayesian DCF Intrinsic $0.38 -72.3% $0.91 -56.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.22 -84.0% $0.86 -59.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OCGN vs PALI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OCGN vs PALI — Which Stock Is More Undervalued?

OCGN scores higher with a 6.6/10 quality rating vs PALI's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Ocugen, Inc. (OCGN) and Palisade Bio, Inc. (PALI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OCGN currently trades at $1.38 with a QOC of 6.6/10, while PALI trades at $2.12 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).